Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* good physical health~Exclusion Criteria:~* history of an abnormal Pap (Papanicolaou) test or abnormal cervical biopsy results~* history of HPV-related condition~* history of known prior vaccination with an HPV vaccine~* pregnant~* user of recreational or illicit drugs~* history of severe allergic reaction, including known allergy to any vaccine component~* immunocompromised~* history of certain medications or is currently taking or has taken certain medications (details will be discussed at the time of consent)~* has thrombocytopenia or other coagulation disorder~* concurrently enrolled in a clinical study of investigational agent

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Adult Women 27- to 45-years Old (Type: EXPERIMENTAL): Adult women 27- to 45-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
- Young Adult Women 16- to 26-years Old (Type: ACTIVE_COMPARATOR): Young adult women 16- to 26-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).